down arrow

BioInvent International AB

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: SE0015244520
SEK
29.05
1.9 (7.0%)

Dec 04

OME

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Comparison
Company
Score
Quality
Valuation
Financial
Technical
Saniona AB
Vimian Group AB
Probi AB
Biovica International AB
Intervacc AB
BioInvent International AB
BICO Group AB
Alligator Bioscience AB
Magle Chemoswed Holding AB
Mendus AB
Bio-Works Technologies AB
Why is BioInvent International AB ?
1
Poor long term growth as Operating profit has grown by an annual rate -181.56% of over the last 5 years
2
Risky -
  • The stock is trading risky as compared to its average historical valuations
  • Over the past year, while the stock has generated a return of -37.99%, its profits have risen by 23.9%
3
Below par performance in long term as well as near term
  • Along with generating -37.99% returns in the last 1 year, the stock has also underperformed OMX Stockholm 30 in the last 3 years, 1 year and 3 months
stock-recommendationReal-Time Research Report
Verdict Report
How much should you sell?
  1. All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is BioInvent International AB for you?

High Risk, Low Return

Absolute
Risk Adjusted
Volatility
BioInvent International AB
-33.83%
-0.37
62.46%
OMX Stockholm 30
8.01%
0.51
18.11%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors
Factor
Value
Sales Growth (5y)
27.03%
EBIT Growth (5y)
-181.56%
EBIT to Interest (avg)
-263.48
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.95
Sales to Capital Employed (avg)
0.11
Tax Ratio
0.03%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0.91%
ROCE (avg)
0
ROE (avg)
0
stock-recommendationValuation
Valuation Scorecard stock-summary
stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
2.30
EV to EBIT
-3.35
EV to EBITDA
-3.57
EV to Capital Employed
48.19
EV to Sales
4.24
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-1437.52%
ROE (Latest)
-36.01%
stock-recommendationTechnicals
Technical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
Mildly Bearish
Mildly Bullish
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
Analyse All Technical Factors stock-recommendation
stock-recommendationFinancial Trend
Financial Trend Scorecard stock-summary
stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

17What is working for the Company
NET PROFIT(HY)

Higher at SEK -233.51 MM

DEBT-EQUITY RATIO (HY)

Lowest at -94.45 %

RAW MATERIAL COST(Y)

Fallen by 0% (YoY

NET SALES(Q)

Highest at SEK 22.06 MM

OPERATING PROFIT MARGIN(Q)

Highest at -535.29 %

-11What is not working for the Company
OPERATING CASH FLOW(Y)

Lowest at SEK -434.57 MM

NET PROFIT(HY)

At SEK -233.51 MM has Grown at -33.36%

ROCE(HY)

Lowest at -46.75%

Here's what is working for BioInvent International AB
Net Sales
At SEK 22.06 MM has Grown at 97.47%
over average net sales of the previous four periods of SEK 11.17 MM
MOJO Watch
Near term sales trend is extremely positive

Net Sales (SEK MM)

Net Profit
Higher at SEK -233.51 MM
than preceding 12 month period ended Mar 2025
MOJO Watch
In the half year the company has already crossed Net Profit of the previous twelve months

Net Profit (SEK MM)

Debt-Equity Ratio
Lowest at -94.45 % and Grown
In each half year in the last five Semi-Annual periods
MOJO Watch
The company has been reducing its borrowing as compared to equity capital

Debt-Equity Ratio

Net Sales
Highest at SEK 22.06 MM
in the last five periods
MOJO Watch
Near term sales trend is positive

Net Sales (SEK MM)

Operating Profit Margin
Highest at -535.29 %
in the last five periods
MOJO Watch
Company's profit margin has improved

Operating Profit to Sales

Raw Material Cost
Fallen by 0% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Depreciation
Highest at SEK 5.14 MM
in the last five periods
MOJO Watch
The expenditure on assets done by the company may have gone into operation

Depreciation (SEK MM)

Here's what is not working for BioInvent International AB
Net Profit
At SEK -233.51 MM has Grown at -33.36%
Year on Year (YoY)
MOJO Watch
Near term Net Profit trend is very negative

Net Profit (SEK MM)

Operating Cash Flow
Lowest at SEK -434.57 MM and Fallen
In each year in the last three years
MOJO Watch
The company's cash revenues from business operations are falling

Operating Cash Flows (SEK MM)

Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."